rabbit pab cd86 antibody  (ABclonal Biotechnology)

Journal: Materials Today Bio

Article Title: A macrophage-like biomimetic nanoparticle with high-efficiency biofilm disruption and innate immunity activation for implant-related infection therapy

doi: 10.1016/j.mtbio.2025.101575

Figure Lengend Snippet: Immunomodulatory effects of F/R@PM on macrophages in vitro. ( A ) Typical scatter plots of macrophage surface markers CD86 (M1 macrophage marker) as detected using a flow cytometer. ( B ) Representative western blot results of the expression of CD86 protein after various treatments. ( C ) Corresponding quantitative analyses of western blot results (n = 3, ∗∗ P < 0.01). ( D ) ELISA results of cytokines (TNF- α and IL-6) secreted by RAW264.7 in different groups (n = 3, ∗∗ P < 0.01). ( E ) Counted results of phagocytized S. aureus by RAW264.7 treated in different conditions (n = 3, ∗∗ P < 0.01). ( F ) Swallowed S. aureus was observed by using TEM. Yellow arrows indicate S. aureus . (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: For IHC analysis, tissue slices were incubated with the primary antibodies anti-CD86 Rabbit pAb (1:100, Bioss), TNF-α Rabbit pAb (1:100, Servicebio), and IL-6 Rabbit pAb (1:100, Servicebio) for 12 h, followed by secondary antibody HRP-conjugated goat anti-rabbit IgG ([H + L], 1:100, Servicebio) for 0.5 h. The diaminobenzidine detection kit was used to visualize the binding sites.

Techniques: In Vitro, Marker, Flow Cytometry, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay

Journal: Materials Today Bio

Article Title: A macrophage-like biomimetic nanoparticle with high-efficiency biofilm disruption and innate immunity activation for implant-related infection therapy

doi: 10.1016/j.mtbio.2025.101575

Figure Lengend Snippet: Immunomodulatory function of F/R@PM in vivo. ( A ) Immunohistochemical images of peripheral tissues stained with CD86 antibody. ( B ) Immunohistochemical images of peripheral tissues stained with TNF- α and IL-6 antibody. ( C ) ELISA results of peripheral tissue homogenates. (n = 3, ∗∗ P < 0.01).

Article Snippet: For IHC analysis, tissue slices were incubated with the primary antibodies anti-CD86 Rabbit pAb (1:100, Bioss), TNF-α Rabbit pAb (1:100, Servicebio), and IL-6 Rabbit pAb (1:100, Servicebio) for 12 h, followed by secondary antibody HRP-conjugated goat anti-rabbit IgG ([H + L], 1:100, Servicebio) for 0.5 h. The diaminobenzidine detection kit was used to visualize the binding sites.

Techniques: In Vivo, Immunohistochemical staining, Staining, Enzyme-linked Immunosorbent Assay

Journal: Science Advances

Article Title: Targeting VPS18 hampers retromer trafficking of PD-L1 and augments immunotherapy

doi: 10.1126/sciadv.adp4917

Figure Lengend Snippet: ( A ) Flowchart of tissue distribution of RDN in C57BL/6 mice detected by mass spectrometry imaging. ( B ) Representative mass spectrometry image of the distribution of RDN in the tissue at 12 and 24 hours after RDN (20 mg/kg) was injected into the tail vein. The red-green-blue (RGB) image was generated by “MIRION,” which was converted from the original file after setting a unified threshold. ( C ) Flowchart of pharmacodynamic study of RDN combined with anti–CTLA-4 in the lung of C57BL/6 mice to construct an in-situ model of lung cancer. C57BL/6 mice were randomly divided into the model group, RDN (10 mg/kg), RDN (10 mg/kg) combined with the anti–CTLA-4 group (100 μg), and the anti–CTLA-4 group (100 μg). Each group consisted of 14 mice, 6 for pharmacodynamic evaluation and 8 for survival analysis. ( D ) Analyzed fluorescence signals using an in vivo imaging instrument (PerkinElmer) in mice levels ( n = 6). ( E ) Survival analysis of mice in each group ( n = 8). ( F ) Anatomical map of lung tissue of each group of mice ( n = 5). ( G ) Hematoxylin and eosin (H&E) staining of lung tissue of each group of mice. Scale bars, 200 μm. Immunohistochemistry (IHC) staining displays Ki67 expression of lung tissue of each group. Scale bars, 20 μm. ( n = 6). ( H ) IHC staining displays CD4, CD8, FOXP3, GzmB, and PD-L1 expressions of lung tissue from each group. Representative images of six biologically independent samples. Scale bar, 200 μm. ( I ) Quantitative results of IHC staining for CD4, CD8, Foxp3, Ki67, GzmB, and PD-L1 (relative to placebo). Data are means ± SD, n = 3. Statistical significance was determined by a two-sided, unpaired t test. * P < 0.05, ** P < 0.01, and *** P < 0.001.

Article Snippet: Ki67 Rabbit pAb antibody, GzmB Rabbit pAb antibody, CD86 Rabbit pAb antibody, and CD56 Rabbit pAb antibody were purchased from ABclonal Technology Co., Ltd. CD4 antibody, CD8 antibody, and Foxp3 antibody were purchased from Servicebio Technology Co., Ltd.

Techniques: Mass Spectrometry, Imaging, Injection, Generated, Construct, In Situ, Fluorescence, In Vivo Imaging, Staining, Immunohistochemistry, Expressing